相似文献
1
Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD.
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2673-2674.e3. doi: 10.1016/j.cgh.2020.11.005. Epub 2020 Nov 3.
2
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742.
3
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4.
4
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Hepatology. 2015 May;61(5):1547-54. doi: 10.1002/hep.27368. Epub 2015 Mar 23.
5
Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
Scand J Gastroenterol. 2012 Jan;47(1):108-15. doi: 10.3109/00365521.2011.634024. Epub 2011 Nov 30.
6
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
Liver Int. 2016 Aug;36(8):1213-20. doi: 10.1111/liv.13076. Epub 2016 Feb 24.
7
Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Scand J Gastroenterol. 2020 Jun;55(6):706-711. doi: 10.1080/00365521.2020.1766554. Epub 2020 Jun 1.
8
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
9
Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study.
Scand J Gastroenterol. 2017 Aug;52(8):881-885. doi: 10.1080/00365521.2017.1315169. Epub 2017 Apr 27.
10
High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2081-2090.e9. doi: 10.1016/j.cgh.2019.12.025. Epub 2019 Dec 27.
引用本文的文献
1
Quantification of using the digital polymerase chain reaction as a liver fibrosis marker.
World J Hepatol. 2025 Apr 27;17(4):102027. doi: 10.4254/wjh.v17.i4.102027.
2
Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score in diagnosing at-risk MASH.
Eur Radiol. 2025 Jun;35(6):3599-3609. doi: 10.1007/s00330-024-11215-3. Epub 2024 Dec 5.
3
Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study.
Obes Surg. 2024 May;34(5):1569-1574. doi: 10.1007/s11695-024-07180-x. Epub 2024 Mar 19.
4
A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Intern Med. 2024 May 1;63(9):1185-1190. doi: 10.2169/internalmedicine.2248-23. Epub 2023 Sep 29.
5
Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study.
JHEP Rep. 2023 Feb 2;5(4):100692. doi: 10.1016/j.jhepr.2023.100692. eCollection 2023 Apr.
6
Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist.
Cardiovasc Diabetol. 2022 Jul 12;21(1):130. doi: 10.1186/s12933-022-01564-y.
7
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.
Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0. Epub 2021 Nov 23.
8
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
Gut. 2022 May;71(5):983-990. doi: 10.1136/gutjnl-2021-324264. Epub 2021 Apr 21.
本文引用的文献
1
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4.
2
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Hepatology. 2020 Oct;72(4):1219-1229. doi: 10.1002/hep.31121. Epub 2020 Oct 9.
3
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565.
4
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
Hepatology. 2019 Nov;70(5):1841-1855. doi: 10.1002/hep.30672.
5
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
6
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
7
Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
Hepatology. 2005 Jun;41(6):1313-21. doi: 10.1002/hep.20701.
Zotero 插件